| How to prepare reproducible, homogeneous, and hydrolytically stable aminosilane-derived layers on silica M Zhu, MZ Lerum, W Chen Langmuir 28 (1), 416-423, 2012 | 524 | 2012 |
| SAM-based cell transfer to photopatterned hydrogels for microengineering vascular-like structures N Sadr, M Zhu, T Osaki, T Kakegawa, Y Yang, M Moretti, J Fukuda, ... Biomaterials 32 (30), 7479-7490, 2011 | 124 | 2011 |
| Pembrolizumab in combination with neoadjuvant chemoradiotherapy for patients with resectable adenocarcinoma of the gastroesophageal junction M Zhu, C Chen, NR Foster, C Hartley, T Mounajjed, MA Salomao, ... Clinical Cancer Research 28 (14), 3021-3031, 2022 | 46 | 2022 |
| The role of microbiome in pancreatic cancer JJ Li, M Zhu, PC Kashyap, N Chia, NH Tran, RR McWilliams, ... Cancer and Metastasis Reviews 40, 777-789, 2021 | 37 | 2021 |
| Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: a phase I dose escalation and expansion study A Wang-Gillam, KH Lim, R McWilliams, R Suresh, AC Lockhart, A Brown, ... Clinical Cancer Research 28 (24), 5254-5262, 2022 | 33 | 2022 |
| Increased length of stay associated with antibiotic use in older adults with advanced cancer transitioned to comfort measures R Datta, M Zhu, L Han, H Allore, V Quagliarello, M Juthani-Mehta American Journal of Hospice and Palliative Medicine® 37 (1), 27-33, 2020 | 22 | 2020 |
| Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers TL Hogenson, H Xie, WJ Phillips, MD Toruner, JJ Li, IP Horn, DJ Kennedy, ... JCI insight 7 (22), 2022 | 21 | 2022 |
| A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors M Zhu, JR Molina, GK Dy, GA Croghan, Y Qi, J Glockner, LJ Hanson, ... Investigational New Drugs 38, 1755-1762, 2020 | 14 | 2020 |
| Gold-black micropillar electrodes for microfluidic ELISA of bone metabolic markers S Numthuam, T Ginoza, M Zhu, H Suzuki, J Fukuda Analyst 136 (3), 456-458, 2011 | 12 | 2011 |
| Management of non-colorectal digestive cancers with microsatellite instability M Zhu, Z Jin, JM Hubbard Cancers 13 (4), 651, 2021 | 8 | 2021 |
| Antimicrobial therapy for asymptomatic bacteriuria or candiduria in advanced cancer patients transitioning to comfort measures R Datta, T Wang, M Zhu, LM Dembry, L Han, H Allore, V Quagliarello, ... Infection Control & Hospital Epidemiology 40 (4), 470-472, 2019 | 7 | 2019 |
| Understanding suboptimal response to immune checkpoint inhibitors M Zhu, H Zhang, KS Pedersen, NR Foster, BL Jaszewski, X Liu, JB Hirdler, ... Advanced Biology 7 (4), 2101319, 2023 | 6 | 2023 |
| Phase II trial of bevacizumab monotherapy in pancreatic neuroendocrine tumors M Zhu, BA Costello, J Yin, AM Pettinger, JR Strosberg, C Erlichman, ... Pancreas 50 (10), 1435-1439, 2021 | 6 | 2021 |
| Acquired immunotherapy resistance in gastrointestinal cancers M Zhu, TS Bekaii-Saab JAMA Network Open 5 (3), e224646-e224646, 2022 | 4 | 2022 |
| A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced … WW Ma, M Zhu, ET Lam, JR Diamond, GK Dy, GA Fisher, LW Goff, ... Cancer chemotherapy and pharmacology 87, 779-788, 2021 | 4 | 2021 |
| Phase Ib open-label study to evaluate safety, tolerability, immunogenicity, and efficacy of multiple subcutaneous injections of PolyPEPI1018 vaccine as an add-on immunotherapy … JM Hubbard, TJ Zemla, RP Graham, Z Jin, M Zhu, JL Mitchell, E Novo, ... Journal of Clinical Oncology 41 (4_suppl), 147-147, 2023 | 2 | 2023 |
| Bim and CX3CR1/granzyme B in circulating CD8+ T cells are predictive biomarkers for PD-1 blockade therapy M Zhu, H Zhang, NR Foster, H Dong, TS Bekaii-Saab, BL Jaszewski, ... Cancer Research 80 (16_Supplement), 4467-4467, 2020 | 2 | 2020 |
| Homologous recombination repair defect may predict treatment response to peptide receptor radionuclide therapy for neuroendocrine tumors M Zhu, MB Sonbol, T Halfdanarson, T Hobday, D Ahn, WW Ma, ... The Oncologist 25 (8), e1246-e1248, 2020 | 2 | 2020 |
| Trial in progress: Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated metastatic pancreatic cancer. RR McWilliams, PM Kasi, NR Foster, M Zhu, RM Carr, WW Ma, ... Journal of Clinical Oncology 41 (4_suppl), TPS780-TPS780, 2023 | 1 | 2023 |
| Resilient CD8+ T cells maintain a high cytotoxic capacity by balancing ROS via ME1 upregulation JK Gicobi, Z Mao, G DeFranco, Y Li, X Liu, JB Hirdler, VV Vianzon, ... bioRxiv, 2022.11. 25.517988, 2022 | 1 | 2022 |
